ArticleEuropean journal of nuclear medicine and molecular imaging2019
Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Traumatic Brain Injury and Alzheimer's Disease Biomarkers: A Systematic Review of Findings from Amyloid and Tau Positron Emission Tomography.Journal of neurotrauma · 2025Pooled it
- Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.The journal of prevention of Alzheimer's disease · on this mapTrial
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- First evaluation in multiple sclerosis using PET tracer [European journal of nuclear medicine and molecular imaging · 2026Article
- Baseline Findings from Dual-Phase Amyloid PET Study in Newly Diagnosed Multiple Sclerosis: Exploring Its Potential as a Biomarker of Myelination and Neurodegeneration.Journal of personalized medicine · 2025Article
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Myelin Imaging of the Spinal Cord in Animal Models and Patients with Multiple Sclerosis Using [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Vascular risk factors and neuroimaging heterogeneity across different white matter hyperintensities distribution patterns.Frontiers in human neuroscience · 2025Article
- Article
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
- Quantitative myelin imaging with MRI and PET: an overview of techniques and their validation status.Brain : a journal of neurology · 2023Review
- Cortical amyloid-beta burden is associated with changes in intracortical myelin in cognitively normal older adults.Translational psychiatry · 2023Article
- Quantitative assessment of myelin density using [European journal of nuclear medicine and molecular imaging · 2022Article
- Article
- Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage.Alzheimer's research & therapy · 2022Article
- The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress.Aging and disease · 2022Article
- Positron emission tomography in multiple sclerosis - straight to the target.Nature reviews. Neurology · 2021Review
- Reduced [European journal of nuclear medicine and molecular imaging · 2021Article
- Article
- Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis.Brain sciences · 2021Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe disease course of multiple sclerosis (MS) is unpredictable, and reliable prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid tracers is a promising tool for evaluating white matter (WM) damage and repair. Our aim was to investigate amyloid uptake in damaged (DWM) and normal-appearing WM (NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal fluid (CSF) β-amyloid
methodsTwelve MS patients were recruited and divided according to their disease activity into active and non-active groups. All participants underwent neurological examination, neuropsychological testing, lumbar puncture, brain magnetic resonance (MRI) imaging, and
resultsWe found a lower SUV in DWM compared to NAWM (p < 0.001) in all patients. Decreased NAWM-SUV was observed in the active compared to non-active group (p < 0.05). Considering only active patients, NAWM volume correlated with NAWM-SUV (p = 0.01). Interestingly, CSF Aβ concentration was a predictor of both NAWM-SUV (r = 0.79; p = 0.01) and NAWM volume (r = 0.81, p = 0.01).
conclusionsThe correlation between CSF Aβ levels and NAWM-SUV suggests that the predictive role of β-amyloid may be linked to early myelin damage and may reflect disease activity and clinical progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.